New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:07 EDTINSYInsys receives FDA orphan drug designation for pharmaceutical cannabidiol
Insys Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to its pharmaceutical cannabidiol for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy. The company said, "We have the unique opportunity to test a controlled pharmaceutical CBD product for Lennox-Gastaut Syndrome, and our company is committed to advancing cannabinoid therapies that have the potential to provide significant medical benefits to patients across multiple indications. We expect to file an Investigational New Drug Application for CBD in 2H14."
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
13:10 EDTINSYInsys Therapeutics weakness a buying opportunity, says RBC Capital
Subscribe for More Information
12:25 EDTINSYInsys Therapeutics drops following arrest of Alabama doctors
Shares of Insys Therapeutics (INSY) are sharply lower in early afternoon trading after FOX10 News in Alabama reported that Dr. John Patrick Couch and Dr. Xiulu Ruan of Physicians' Pain Specialists of Alabama Pain Center have been arrested on drug and fraud charges. Previously, the Southern Investigative Reporting Foundation stated that Ruan and Couch were the leading prescription writers of Subsys, which is Insys' sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients, by an "impressive margin." Shares of Insys are down 8.4% to $54.76 in afternoon trading following the news of the arrests of the doctors. Reference Link
12:18 EDTINSYInsys Therapeutics puts active on sharp pullback
Insys Therapeutics June 50 and 55 puts are active on total put volume of 6,500 contracts (100 calls). June put option implied volatility is at 76, July is at 60 compared to its 90-day average of 62. Active put volume suggests traders taking positions for large upside price movement.
08:05 EDTINSYInsys Therapeutics pipeline growing, underappreciated, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use